| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.068 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | KIN001-270 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |